虛擬臨床試驗市場－全球產業規模、佔有率、趨勢、機會和預測，按研究設計、適應症、階段、地區和競爭細分，2020-2030 年

2024 年全球虛擬臨床試驗市場價值為 84.8 億美元，預計到 2030 年將達到 157.6 億美元，複合年成長率為 10.86%。虛擬臨床試驗 (VCT)，也稱為分散試驗或遠端試驗，透過利用數位工具進行遠端註冊、監控和資料收集，徹底改變了臨床研究流程。這些試驗提高了患者的可及性，增強了即時資料捕獲，並簡化了研究操作。技術進步、以患者為中心的試驗模式的推動以及對高效、靈活的研究設計的需求推動了 VCT 的採用。透過消除實地考察的要求，VCT 減少了參與障礙並提高了試驗的包容性。儘管面臨資料隱私和監管複雜性的挑戰，虛擬模型作為傳統試驗限制的永續解決方案正獲得越來越多的關注，為全球研究計畫提供了增強的可擴展性和營運效率。

關鍵市場促進因素

疾病負擔日益加重

主要市場挑戰

資料安全和隱私

主要市場趨勢

遠端監控和穿戴式裝置

目錄

第1章：服務概述

• 市場定義
• 市場範圍
  • 覆蓋市場
  • 考慮學習的年限
  • 主要市場區隔

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球虛擬臨床試驗市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依研究設計（介入性、觀察性、擴展獲取性）
  • 按適應症（腫瘤科、心血管疾病科、其他科）
  • 按階段（第 1 階段、第 2 階段、第 3 階段、第 4 階段）
  • 按公司分類（2024）
  • 按地區
• 市場地圖

第6章：北美虛擬臨床試驗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第7章：歐洲虛擬臨床試驗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太虛擬臨床試驗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲

第9章：南美洲虛擬臨床試驗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東與非洲虛擬臨床試驗市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 併購

第 13 章： 大環境分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章：競爭格局

• Medable, Inc.
• ICON, plc
• Parexel International Corporation
• Medidata Solutions Inc
• Oracle Corp
• Signant Health
• Leo Laboratories Ltd
• IQVIA Inc
• PRA Health Sciences Inc
• Clinical Ink Inc

第 16 章：策略建議

第17章調查會社について,免責事項

The Global Virtual Clinical Trials Market was valued at USD 8.48 billion in 2024 and is projected to reach USD 15.76 billion by 2030, expanding at a CAGR of 10.86%. Virtual clinical trials (VCTs), also referred to as decentralized or remote trials, are revolutionizing the clinical research process by leveraging digital tools for remote enrollment, monitoring, and data collection. These trials improve patient accessibility, enhance real-time data capture, and streamline study operations. The adoption of VCTs is being driven by technological advancements, the push for patient-centric trial models, and the need for efficient, flexible study designs. By eliminating the requirement for physical site visits, VCTs reduce barriers to participation and improve trial inclusivity. Despite challenges around data privacy and regulatory complexities, the virtual model is gaining traction as a sustainable solution to traditional trial limitations, offering enhanced scalability and operational efficiency across global research initiatives.

Key Market Drivers

Growing Burden of Diseases

The rising incidence of chronic and rare diseases worldwide is a major driver fueling the adoption of Virtual Clinical Trials (VCTs). In 2024, over 828 million adults were reported to have diabetes, with nearly half of them untreated, indicating an urgent demand for more efficient research methodologies. Additionally, around 300 million people globally suffer from rare diseases. Traditional clinical trial models often encounter challenges like delayed recruitment and participant dropout, which can hinder medical advancements. VCTs offer a solution by using digital tools to reach broader and more diverse populations, thereby improving trial inclusivity and data relevance. The remote nature of VCTs is particularly advantageous for rare disease research, as these conditions often involve small, geographically dispersed patient groups. VCTs also expedite data collection and allow for real-time monitoring, enabling faster decision-making and adaptive trial protocols. To fully capitalize on these benefits, collaboration among stakeholders is necessary to maintain scientific rigor and regulatory compliance while improving access and outcomes.

Key Market Challenges

Data Security and Privacy

Data security and privacy are key concerns in the Virtual Clinical Trials (VCTs) market due to the extensive use of digital platforms for collecting and managing sensitive health information. The remote and tech-driven model of VCTs introduces heightened risks related to data breaches, unauthorized access, and the potential exposure of personally identifiable health data. Compliance with data protection regulations such as GDPR and HIPAA is particularly complex in multi-regional trials with varied regulatory landscapes. Addressing these issues requires robust encryption standards, secure communication protocols, and multi-factor authentication systems to protect patient data. Informed consent must be transparent and comprehensive, clearly outlining data usage and protection measures. Partnerships between technology providers, regulatory bodies, and cybersecurity experts are essential for establishing reliable frameworks that uphold data integrity and patient trust. Without strong safeguards, breaches can undermine the credibility of VCTs and stall their broader adoption.

Key Market Trends

Remote Monitoring and Wearables

The integration of remote monitoring and wearable devices is a transformative trend reshaping the Virtual Clinical Trials (VCTs) landscape. Wearables such as smartwatches and fitness trackers facilitate continuous, real-time health monitoring in everyday settings, offering rich datasets on parameters like heart rate, activity levels, and sleep patterns. This capability reduces the need for frequent site visits while improving trial accuracy through the collection of objective data. The ability to detect early signs of adverse reactions enhances patient safety and allows for proactive interventions. Additionally, remote monitoring promotes patient engagement by empowering individuals to take an active role in their health journey, which can boost trial adherence. The real-world insights gathered through these devices provide a more holistic view of treatment efficacy and patient experience. However, issues such as data integration, device interoperability, and accuracy must be addressed. Despite these hurdles, wearable-enabled monitoring is enhancing the depth and relevance of clinical trial data, contributing to more effective and efficient studies.

Key Market Players

• Medable, Inc.
• ICON, plc
• Parexel International Corporation
• Medidata Solutions Inc
• Oracle Corp
• Signant Health
• Leo Laboratories Ltd
• IQVIA Inc
• PRA Health Sciences Inc
• Clinical Ink Inc

Report Scope:

In this report, the Global Virtual Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Virtual Clinical Trials Market, By Study Design:

• Interventional
• Observational
• Expanded Access

Virtual Clinical Trials Market, By Indication:

• Oncology
• Cardiovascular Disease
• Others

Virtual Clinical Trials Market, By Phase:

• Phase 1
• Phase 2
• Phase 3
• Phase 4

Virtual Clinical Trials Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Virtual Clinical Trials Market.

Available Customizations:

Global Virtual Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customers

5. Global Virtual Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Study Design (Interventional, Observational, Expanded Access)
  • 5.2.2. By Indication (Oncology, Cardiovascular Disease, Others)
  • 5.2.3. By Phase (Phase 1, Phase 2, Phase 3, Phase 4)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Virtual Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Study Design
  • 6.2.2. By Indication
  • 6.2.3. By Phase
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Virtual Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Study Design
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Phase
  • 6.3.2. Mexico Virtual Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Study Design
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Phase
  • 6.3.3. Canada Virtual Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Study Design
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Phase

7. Europe Virtual Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Study Design
  • 7.2.2. By Indication
  • 7.2.3. By Phase
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Virtual Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Study Design
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Phase
  • 7.3.2. Germany Virtual Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Study Design
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Phase
  • 7.3.3. United Kingdom Virtual Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Study Design
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Phase
  • 7.3.4. Italy Virtual Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Study Design
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Phase
  • 7.3.5. Spain Virtual Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Study Design
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Phase

8. Asia-Pacific Virtual Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Study Design
  • 8.2.2. By Indication
  • 8.2.3. By Phase
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Virtual Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Study Design
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Phase
  • 8.3.2. India Virtual Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Study Design
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Phase
  • 8.3.3. South Korea Virtual Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Study Design
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Phase
  • 8.3.4. Japan Virtual Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Study Design
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Phase
  • 8.3.5. Australia Virtual Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Study Design
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Phase

9. South America Virtual Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Study Design
  • 9.2.2. By Indication
  • 9.2.3. By Phase
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Virtual Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Study Design
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Phase
  • 9.3.2. Argentina Virtual Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Study Design
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Phase
  • 9.3.3. Colombia Virtual Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Study Design
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Phase

10. Middle East and Africa Virtual Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Study Design
  • 10.2.2. By Indication
  • 10.2.3. By Phase
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Virtual Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Study Design
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Phase
  • 10.3.2. Saudi Arabia Virtual Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Study Design
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Phase
  • 10.3.3. UAE Virtual Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value & Volume
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Study Design
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Phase

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Medable, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. ICON, plc
• 15.3. Parexel International Corporation
• 15.4. Medidata Solutions Inc
• 15.5. Oracle Corp
• 15.6. Signant Health
• 15.7. Leo Laboratories Ltd
• 15.8. IQVIA Inc
• 15.9. PRA Health Sciences Inc
• 15.10. Clinical Ink Inc

16. Strategic Recommendations

17. About Us & Disclaimer